Merck KGaA Archives | BioInformant

BioInformant, a specialized market research firm serving the life science industry, announces the release of its latest report, “Stem Cell Research Products: Opportunities, Tools & Technologies.” The report combines technology-derived market data with end-user survey findings, exploring current market conditions and providing guidance to companies looking to develop strategically positioned stem cell product lines.

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including: embryonic, perinatal, adult, and cancer stem cells. Of interest to researchers is the potential for the use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders. Also, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to pharmaceutical companies.

To facilitate this research, a vast stem cell research products market is emerging. Large companies selling stem cell research products include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Lonza, Clontech (a Takara Bio Company), and GE Healthcare Life Sciences. Products offered by these companies include: antibodies to stem cell antigens, bead-based stem cell separation systems, stem cell protein purification and analysis tools, tools for DNA and RNA-based characterization of stem cells, stem cell culture and media reagents, stem cell specific growth factors and cytokines, tools for stem cell gene regulation, a range of stem cell services, tools for in vivo and in vitro stem cell tracking, and stem cell lines.

“A more in-depth understanding of the needs of scientists studying stem cells is of growing importance as the field becomes more complex and funding sources become harder to obtain,” explained Cade Hildreth, President/CEO of BioInformant.com.

This market report includes:

An overview of stem cell research applications, including priorities by segment
A breakdown of stem cell product categories
Market assessment, including grant, patent, clinical trial, and scientific publication rate analysis
Overview of stem cell funding sources, trends, and amounts (domestic and international)
Market size valuations
Historical and future growth projections for the stem cell research products market
Competitive analysis of stem cell research product companies
Communications strategies for accessing the marketplace
End-user survey of stem cell scientists

Released February 2016, “Stem Cell Research Products: Opportunities, Tools & Technologies ” explores current market conditions within the stem cell research products market, provides strategic guidance for competing within the industry, and quantifies important trends, metrics, and findings to guide the decision-making of competitors across the stem cell research products marketplace.

Click here to view the full Executive Summary and Table of contents for the report: https://bioinformant.wpengine.com/product/stem-cell-research-products-opportunities-tools-and-technologies/.

Want to be better informed than your competition? Get future stem cell industry updates.

About Us

BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.

Click here to view our global strategic reports for the stem cell and cord blood industry.

Merck KGaA is best known for being a major player in the pharmaceutical space. More specifically, the company is a multinational chemical, pharmaceutical and life sciences company headquartered in Darmstadt, Germany, that boasts over 40,000 employees spread across 70+ countries worldwide.

For those of us involved the stem cell world, Sigma-Aldrich is best known as a provider of research products and reagents. The company offers a diverse suite of stem cell specific research products, including a complete line of stem cell products for embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) research, as well as mesenchymal stem cell research, neural stem cell reagents, and more.

However, Sigma-Aldrich is actuallydiversified as well. It is an American multinational chemical, life science, and biotechnology company, headquartered in St. Louis, MO. It has nearly 10,000 employees spread across more than 40 countries worldwide and is an honored member of the Fortune 1000, a list of the 1000 largest American companies, ranked by revenue.

Previously announced in September of 2014, Merck KGaA stated it would acquire Sigma-Aldrich for $17.0 billion. However, the deal required approval from national regulatory agencies within Europe before it could become official. Specifically, the board of directors for Sigma-Aldrich approved an agreement under which Merck KGaA would acquire Sigma-Aldrich for $140.00 per share in cash. At that time, it was unknown when the deal would close, although a mid-2015 timeline was loosely anticipated.

In major news released today, November 18, 2015, Merck KGaA has announced that it has completed its acquisition of Sigma-Aldrich Corporation for $140 per share, a deal valued at $17.0 billion.

For those unfamiliar with the history of Merck KGaA, EMD Millipore is an American-based subsidiary of its German parent company, Merck KGaA. It is known as Merck Millipore outside the United States and Canada.

Therefore, EMD Millipore and Sigma-Aldrich will now be one organization within Merck KGaA, which will be known as “MilliporeSigma” within the U.S. and Canada.

As the deal is valued at approximately $17 billion, it is a massive acquisition with the life science sector. The completed deal resulted from recent approvals provided by the European Commission, which was the last remaining antitrust condition necessary to allow Sigma-Aldrich to become a fully owned business unit of Merck KGaA. Importantly, Merck KGaA will now offer a diverse portfolio of more than 300,000 products, making it the leading player in a $130 billion global life science industry.

Congratulations to all involved with this massive transaction and here’s to hoping the it will continue to emphasize the development of new and progressive stem cell research products and reagents.

Need detailed market analysis for the stem cell or cord blood industry? View our global strategic reports here.